Independent fund research. Built on SEC filings.

How we research funds

ETF overlap

VGHCX vs SCHLX overlap: 57% of top holdings shared

Bottom line

How much do VGHCX and SCHLX overlap?

57% of their top holdings overlap by weight. 13 securities appear in both funds' top 25, making up 44.2% of VGHCX's assets and 52.6% of SCHLX's. They share a meaningful core but differ in the rest of the portfolio.

Updated Nov 22, 2026

Overlap at a glance

VGHCXSCHLX
Weight overlap (top 25)57%
Shared holdings13
Weight in shared holdings44.2%52.6%
Total positions9765
Expense ratio0.33%1.06%
Holdings as ofJul 31, 2026May 31, 2026

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Holdings VGHCX and SCHLX have in common

Holding% of VGHCX% of SCHLXOverlap
Eli Lilly & Co8.61%13.85%8.61%
Merck & Co Inc5.44%4.85%4.85%
Johnson & Johnson4.83%6.19%4.83%
AstraZeneca PLC4.59%3.80%3.80%
UnitedHealth Group Inc4.05%5.73%4.05%
Intuitive Surgical Inc2.52%2.69%2.52%
Cencora Inc2.47%1.26%1.26%
Vertex Pharmaceuticals Inc2.36%2.45%2.36%
AbbVie Inc2.30%4.90%2.30%
Danaher Corp2.18%2.13%2.13%
Regeneron Pharmaceuticals Inc2.14%1.43%1.43%
Boston Scientific Corp1.53%2.10%1.53%
Roche Holding AG1.18%1.24%1.18%

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Free weekly newsletter

The Fund Letter

Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.

Free. Unsubscribe anytime. We never sell your email.

What each fund holds that the other doesn't

Top-25 holdings that appear in only one of the two funds' top 25.

Only in VGHCX

  1. Gsk Plc — 3.00%
  2. Edwards Lifesciences Corp — 2.56%
  3. CVS Health Corp — 2.52%
  4. Novartis AG — 1.91%
  5. Elevance Health Inc — 1.83%
  6. Argenx SE — 1.68%
  7. HCA Healthcare Inc — 1.68%
  8. Ucb Sa — 1.67%
  9. Agilent Technologies Inc — 1.49%
  10. Biogen Inc — 1.46%
  11. Galderma Group AG — 1.37%
  12. Dexcom Inc — 1.18%

Only in SCHLX

  1. Thermo Fisher Scientific Inc — 3.46%
  2. Novartis AG — 2.90%
  3. Amgen Inc — 2.88%
  4. Gilead Sciences Inc — 2.78%
  5. Stryker Corp — 2.61%
  6. Abbott Laboratories — 2.39%
  7. McKesson Corp — 2.05%
  8. Novo Nordisk A/S — 1.73%
  9. Medtronic PLC — 1.54%
  10. Bristol-Myers Squibb Co — 1.50%
  11. Cardinal Health Inc — 1.34%
  12. Pfizer Inc — 1.17%

Asset mix

Asset typeVGHCXSCHLX
Stocks97.6%99.6%
Repurchase agreements2.2%—
Cash & short-term funds0.1%0.5%

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Country mix

CountryVGHCXSCHLX
US77.6%85.7%
GB7.6%3.8%
CH4.5%5.2%
JP4.8%—
BE3.4%—
DK1.4%1.7%
IE—1.5%
FR—1.0%

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Check another pair

FAQ

How much do VGHCX and SCHLX overlap?
About 57% by weight. 13 securities appear in both funds' top 25 holdings; they make up 44.2% of VGHCX's assets and 52.6% of SCHLX's. They share a meaningful core but differ in the rest of the portfolio.
What stocks do VGHCX and SCHLX have in common?
The largest shared holdings are Eli Lilly & Co, Merck & Co Inc, Johnson & Johnson, UnitedHealth Group Inc, AstraZeneca PLC.
Should I own both VGHCX and SCHLX?
They overlap in part. Owning both concentrates you in the shared names; check that the combined weight in those stocks is what you intend.
Which holds more stocks, VGHCX or SCHLX?
VGHCX is broader, with 97 positions versus 65 for SCHLX. Overlap here is measured on each fund's top 25 holdings, which carry most of the weight.

Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.